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Abstract: 
The drug delivery system (DDS) changes the formulation techniques and have made a great break-through 
progress. Started a simplest pill formulation and gradually improve the techniques regarding the new symptoms and 
indications and breakthrough in the developments of formulation to more sophisticated controlled release 
formulations. Polymers are the major components for the development of controlled release formulations. 
Chemicals included the magnesium stearate, Diltiazem HCl, lactose, polymers (Cabapol and Eudragit derivative) 
monobasic potassium phosphate, starch, CMC, and other of analytical grade. Friabilator, Disintegration 
Apparatus, Syringes, Beakers, Dissolution Apparatus, Balance, UV-Visible Spectrophotometer, PH-meter, Hardness 
tester, volumetric flasks, Test tubes, Single Punch Machine, Verniar caliper and pre-formulation studies done. This 
study concluded that he different types of polymers were used in different combination which showed its physical 
characteristics according to the specifications mentioned in standards. 
Corresponding author: 
Mahira Tabassum,  
Faculty of Pharmacy & health Sciences,  
University of Balochistan; 
Pakistan. 
 
 
Please cite this article in press as Mahira Tabassum et al., Formulation Preparation and Physical Characteristics 
of Cr Diltiazem Hcl with Different Polymer Combinations, Indo Am. J. P. Sci, 2017; 4(12). 
QR code 
 
 
IAJPS 2017, 4 (12), 4248-4252                  Mahira Tabassum et al                    ISSN 2349-7750 
 
w w w . i a j p s . c o m  
 
Page 4249 
INTRODUCTION:  
In the last few decades, the drug delivery system 
(DDS) changes the formulation techniques and has 
made a great break-through progress. Started a 
simplest pill formulation and gradually improve the 
techniques regarding the new symptoms and 
indications and breakthrough in the developments of 
formulation to more sophisticated controlled release 
formulations (1). The formulations now turned in to 
the targeted delivery on tissues and cells (2). To 
achieve therapeutic blood plasma level is now made 
possible by Control Release dosage form which also 
enhances the therapeutic efficacy and patient 
compliance of those drugs having very short half-life 
(3). As compare to the conventional dosage form the 
Controlled release drugs releases the active 
ingredient/ingredients at rates, which are significantly 
different (4). The active ingredient releases from the 
CR formulation systems is predictable, reproducible 
(5). It also releases at required rate as compare to the 
traditional dosage forms which releases the active 
ingredient by the process of dissolution and/or 
diffusion (6). Thus, in traditional drug delivery 
systems the amount of drug can fluctuate in plasma 
widely and it may cause side effects (7).  
Polymers are the major components for the 
development of controlled release formulations (8). 
They may be synthetic or natural (9). Synthetic 
polymers like eudragit is non-biodegradable, 
amorphous non-toxic and non-absorbable (10). As 
carbopol is a natural polymer which is suitable for 
matrix structures (11). The formulations containing 
carbopol 974P was considerably prolonged in 
concentration (12). Diltiazem is widely used calcium 
antagonist for the treatment of both hypertension and 
angina pectoris (13). Diltiazem produces the 
antihypertensive effects by relaxing the vascular 
smooth muscles and it decreases the peripheral 
resistance. Diltiazem has shown to produce enhance 
in exercise tolerance. It is one of the abilities of 
Diltiazem which reduces the myocardial oxygen 
demand. The half-life of Diltiazem is in between 3.0-
4.5 hours which is very suitable to formulate CR 
matrix tablets (13). 
 
 
METHODOLOGY: 
Chemicals   
All Chemicals included the magnesium stearate, 
Diltiazem HCl, lactose, polymers (cabapol and 
eudragit derivative) monobasic potassium phosphate, 
starch, CMC, and other of analytical grade. 
 
Instruments   
Friabilator, Disintegration Apparatus, Syringes, 
Beakers, Dissolution Apparatus, Balance, UV-Visible 
Spectrophotometer, PH-meter, Hardness tester, 
volumetric flasks, Test tubes, Single Punch Machine, 
Verniar caliper.  
 
Pre-formulation Studies 
1. Particles size distribution 
Particle size was analyzed by the help of 
different sieves which were specified according 
to the official specification. 
 
Construction of Standard Curve of the active 
ingredient 
According to the specified specifications 
standard cure was done by the help of UV 
visible spectrophotometer. 
2. Solubility studies 
 
Formulation development 
Each tablet would be prepared according to the 
specifications and dose, mixing the drug and polymer 
by different ratios i.e 10.1, 10.2, 10.3 and the 
polymers 50-50%. 
 
Preparation CR Matrix tablets. 
According to the specified standard protocol matrix 
CR tablet were prepared at different drug and 
polymers + polymer ratios prepared the matrix tablets 
on single punch tableting machine. 
Physical Characterization of the double layered 
CR Tablets. 
All following physical tests would be performed  
1. Friability 
2.  Hardness 
3.  Thickness 
4.  Weight variation by standard procedure 
accordingly. 
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Table 1: Formulation development of Diltiazem HCl 100mg CR Matrix Tablets 
 
Drug + Polymer 
Ratio 
 Drug 
Diltiazem 
HCl) 
Polymers 
 
  
Lubricant 
Mg St. 
0.5% 
 
 
Spray dried 
Lactose) 
 
Eudragit RS 100+Xanthan Gum+ 
Carbopol 934 P plus 
 
10 ratio1 60 mg 6mg 0.5mg 33.5mg 
10 ratio2 60 mg 12mg 0.5mg 27.5mg 
10 ratio3 60 mg 18mg 0.5mg 21.5mg 
 
Table 2: Formulation development of Diltiazem HCl 100mg CR Matrix Tablets 
 
Drug + Polymer 
Ratio 
 Drug 
Diltiazem 
HCl 
Polymers 
 Lubricant (Mg 
St. 0.5%) 
 
 
Filler 
Spray dried 
Lactose) 
 
Eudragit RS 100+Guar 
Gum+Carbopol 934 P plus 
 
10 ratio 1 60 mg 6mg 0.5mg 33.5mg 
10 ratio 2 60 mg 12mg 0.5mg 27.5mg 
10 ratio 3 60 mg 18mg 0.5mg 21.5mg 
 
RESULTS AND DISCUSSIONS: 
Result of diltiazem HCl standard curve 
Different concentrations of Diltiazem HCl were 
plotted against respective absorbances and straight 
line was obtained showed linearity between 
concentration and absorbance. The R2 (Co-efficient 
of determination was 0.9998 and regression equation 
y=3.5187x+0.0024 was resulted and was used for 
calculations of percent drug release of Diltiazem HCl 
from its different CR matrix tablets. results of 
standard curve which are shown figure 1. 
 
 
Fig.1: Diltiazem hydrochloride standard calibration curve 
Diltiazem HCl solubility in Various Solvents 
Solubility studies were conducted in different 
solvents and at different temperatures (25 oC, 37 oC 
and 40 oC). Solubility was obtained in different 
solvents and highest (1.0mg/ml) in phosphate buffer 
(pH 7.2) and showed that Diltiazem HCl was freely 
soluble at this temperature and was selected as 
dissolution medium for in-vitro drug release studies. 
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Table 3: Diltiazem solubility in various solvents at different temperatures 
 
S. No. Solvent pH 0Temperature in C Solubility (mg/ml) 
1 Phosphate Buffer 6.8 40 0.82 
2 Phosphate Buffer 6.8 37 0.80 
3 Phosphate Buffer 6.8 25 0.79 
4 Phosphate Buffer 7.2 40 0.92 
5 Phosphate Buffer 7.2 37 1.1 
6 Phosphate Buffer 7.2 25 0.89 
7 Distilled Water 7.0 40 0.98 
8 Distilled Water 7.0 37 0.997 
9 Distilled Water 7.0 25 0.978 
 
 
Table 4: Physical Characteristics of CR tablets 
Formulations Diameter  Thickness  Hardness Friability  
Weight 
variation  
Eudragit RS 100 plus Carbopol 
934P plus Xathan gum (10:1) 
6.5 2.3±2.156 8.0 0.012 
 
99.12 
Eudragit RS 100 plus Carbopol 
934P plus Xathan gum (10:2) 
6.5 2.2 7.4 
 
0.132 
 
100.23 
Eudragit RS 100 plus Carbopol 
934P plus Xathan gum (10:3) 
6.5 2.2 9.2 
 
0.015 
 
101.56 
Eudragit RS 100 plus Carbopol 
934P plus Guar gum (10:1) 
6.5 2.3 9.6 
 
0.038 
 
102.45 
Eudragit RS 100 plus Carbopol 
934P plus Guar gum (10:2) 
6.5 2.2 9.0 
 
0.124 
 
100.26 
Eudragit RS 100 plus Carbopol 
934P plus Guar gum (10:3) 
6.5 2.3 8.9 
 
0.006 
 
100.34 
 
Physical Characteristics of CR tablets 
Tablets were elegant in appearance and the thickness 
ranged from 2.2±0.934 to 2.3±2.156, diameter ranged 
from 6.5±0.281 to 6.5±2.363, hardness ranged from 
7.4±0.519 to 9.6±0.325, friability ranged from 
0.006±0.238 to 0.132±1.107 and mean weight of CR 
tablets ranged from 99.12±0.282 to102.45±0.802. 
These results are within acceptable limits given by 
author Javaid, (1993). Results are shown in table 4. 
 
CONCLUSION: 
This study concluded that he different types of 
polymers were used in different combination which 
showed its physical characteristics according to the 
specifications mentioned in standards. The friability 
of the Diltiazem CR tablets was within the limits and 
the hardness is also within the limits. The thickness 
and Diameter showed its results near to the limits. 
Weight variations of all these formulations are within 
the limits. It is concluded that all the results of this 
study were within specified limits which showed that 
this study may further investigate the release profile 
and in-vivo studies.  
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